227 related articles for article (PubMed ID: 34461985)
1. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
[TBL] [Abstract][Full Text] [Related]
2. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.
Badaat I; Mirza S; Padron E; Sallman D; Komrokji R; Song J; Hussaini MO
J Clin Pathol; 2020 Apr; 73(4):209-212. PubMed ID: 31771970
[TBL] [Abstract][Full Text] [Related]
3. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
4. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
5. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
Damm F; Chesnais V; Nagata Y; Yoshida K; Scourzic L; Okuno Y; Itzykson R; Sanada M; Shiraishi Y; Gelsi-Boyer V; Renneville A; Miyano S; Mori H; Shih LY; Park S; Dreyfus F; Guerci-Bresler A; Solary E; Rose C; Cheze S; Prébet T; Vey N; Legentil M; Duffourd Y; de Botton S; Preudhomme C; Birnbaum D; Bernard OA; Ogawa S; Fontenay M; Kosmider O
Blood; 2013 Oct; 122(18):3169-77. PubMed ID: 24047651
[TBL] [Abstract][Full Text] [Related]
6. Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.
Feng Y; Liang H; Han M; Luo X; Zhu Y; Liu B
Hematology; 2023 Dec; 28(1):2220222. PubMed ID: 37288803
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.
Kulasekararaj AG; Jiang J; Smith AE; Mohamedali AM; Mian S; Gandhi S; Gaken J; Czepulkowski B; Marsh JC; Mufti GJ
Blood; 2014 Oct; 124(17):2698-704. PubMed ID: 25139356
[TBL] [Abstract][Full Text] [Related]
8. Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.
Ren Y; Lang W; Mei C; Luo Y; Ye L; Wang L; Zhou X; Xu G; Ma L; Jin J; Tong H
Hematol Oncol; 2023 Feb; 41(1):159-166. PubMed ID: 36316121
[TBL] [Abstract][Full Text] [Related]
9. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
Kanagal-Shamanna R; Montalban-Bravo G; Sasaki K; Darbaniyan F; Jabbour E; Bueso-Ramos C; Wei Y; Chien K; Kadia T; Ravandi F; Borthakur G; Soltysiak KA; Routbort M; Patel K; Pierce S; Medeiros LJ; Kantarjian HM; Garcia-Manero G
Cancer; 2021 Oct; 127(19):3552-3565. PubMed ID: 34161603
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
11. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations.
Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D
Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Characteristics and Prognostic Significance of BCOR/BCORL1 Gene Mutation in Patients with Myelodysplastic Syndromes].
Cen YX; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):2004-2010. PubMed ID: 33283733
[TBL] [Abstract][Full Text] [Related]
13. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
Duchmann M; Yalniz FF; Sanna A; Sallman D; Coombs CC; Renneville A; Kosmider O; Braun T; Platzbecker U; Willems L; Adès L; Fontenay M; Rampal R; Padron E; Droin N; Preudhomme C; Santini V; Patnaik MM; Fenaux P; Solary E; Itzykson R
EBioMedicine; 2018 May; 31():174-181. PubMed ID: 29728305
[TBL] [Abstract][Full Text] [Related]
16. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
17. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
[TBL] [Abstract][Full Text] [Related]
18. Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome.
Jung HA; Jung CW; Jang JH
Korean J Intern Med; 2021 Mar; 36(2):413-423. PubMed ID: 33086776
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Martín I; Villamón E; Abellán R; Calasanz MJ; Irigoyen A; Sanz G; Such E; Mora E; Gutiérrez M; Collado R; García-Serra R; Vara M; Blanco ML; Oiartzabal I; Álvarez S; Bernal T; Granada I; Xicoy B; Jerez A; Calabuig M; Diez R; Gil Á; Díez-Campelo M; Solano C; Tormo M;
Br J Haematol; 2021 Aug; 194(4):708-717. PubMed ID: 34296432
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and characteristics of patients with
Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
